Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male

Echocardiography. 2005 Apr;22(4):333-9. doi: 10.1111/j.1540-8175.2005.03191.x.

Abstract

Fabry disease (alpha-galactosidase A deficiency) is an X-linked recessive lysosomal storage disease in which left ventricular hypertrophy (LVH) is common, and if severe, may mimic hypertrophic obstructive cardiomyopathy. Alcohol-induced percutaneous transluminal septal myocardial ablation (PTSMA) has been used as a safe and effective method to alleviate LVH obstruction in patients with hypertrophic obstructive cardiomyopathy (HCM). We describe a case of a classically affected Fabry 53-year-old male with symptomatic HCM (NYHA class III with exertional angina) who was treated with PTSMA. The procedure safely and effectively alleviated symptomatic left ventricular outflow tract obstruction at long-term follow-up, and the patient's NYHA classification was reduced to NYHA class I to II.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Cardiac Catheterization / methods*
  • Catheter Ablation / methods
  • Echocardiography, Doppler, Color
  • Fabry Disease / complications
  • Fabry Disease / diagnosis*
  • Follow-Up Studies
  • Heart Function Tests
  • Humans
  • Hypertrophy, Left Ventricular / complications
  • Hypertrophy, Left Ventricular / diagnostic imaging
  • Hypertrophy, Left Ventricular / therapy*
  • Male
  • Middle Aged
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome
  • Ventricular Outflow Obstruction / complications
  • Ventricular Outflow Obstruction / diagnostic imaging
  • Ventricular Outflow Obstruction / therapy*